Jun 16, 2020
Biohaven Presents NURTEC(TM) (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
Apr 27, 2020
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC(TM) ODT in the Middle East
Apr 09, 2020
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
Apr 07, 2020
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC(TM) ODT
Mar 25, 2020
2020 Insights into Calcitonin Gene Related Peptide Type 1 Receptor - Featuring Adepthera, Allergan and Amgen Among Others
Feb 10, 2020
Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Sep 10, 2019
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Aug 07, 2019
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jul 09, 2019
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
Jul 01, 2019
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
Jun 24, 2019
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
Apr 03, 2019
Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
Apr 01, 2019
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
Feb 04, 2019
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Jan 07, 2019
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
Nov 15, 2018
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist